Ustekinumab (IL12B) Antibody, Monoclonal

CNTO 1275,TT-20

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.2?It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice.2?It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways.Interleukin (IL)-12 and IL-23 are heterodimeric cytokines that evoke immune and inflammatory responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.The role of IL-12 and IL-23 were implicated in a variety of chronic inflammatory conditions, such as psoriasis and inflammatory bowel diseases. They modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets,2?as CD4+ T cells can differentiate into T-helper (Th) effector lineages based on the environment. Th cells can further activate the downstream pro-inflammatory mediators and transcription factors such as TNF? and IFN? that drive innate and adaptive immunity.

PBS buffer pH7.5

batch dependent

Unconjugated

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Homo sapiens / IL12B [Homo sapiens]

homo sapiens

>95%

Drug Analogues

CHO cells

Optimal dilutions for each application to be determined by the researcher.